Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Abstract

Right from the first confirmed incidence in 2009, the infection rate and deaths from swine flu were on the rise and expected to reach crisis levels at anytime with updated swine flu global statistics showing thousands of confirmed cases in many countries and many leading to deaths. With the rising swine flu epidemic around the globe, Cipla, the Indian upstart pharmaceutical company, took on the giant drug companies by manufacturing Antiflu, a cheaper generic version of the erstwhile available viral drug Tamiflu. With approval from WHO certifying that its drug Antiflu was as effective as Tamiflu, Cipla entered into a deal to sell its Antiflu at cheaper prices. With Roche, as the only patent holder of the existing swine flu drug Tamiflu, governments in various countries were stockpiling it to prevent fatalities from complications associated with the swine flu. With projections estimating that a large chunk of the world's population would become infected with swine flu, experts were of the opinion that the floodgates could open up for upstart companies like Cipla to offer cheaper generic drugs. It remained to be seen whether with a looming swine flu epidemic threatening to infect the entire planet, Cipla's venture to produce cheaper generic versions of a drug required to combat a global health crisis, would be able to yield the desired outcome.
Location:
Industry:
Other setting(s):
2009-2010

About

Abstract

Right from the first confirmed incidence in 2009, the infection rate and deaths from swine flu were on the rise and expected to reach crisis levels at anytime with updated swine flu global statistics showing thousands of confirmed cases in many countries and many leading to deaths. With the rising swine flu epidemic around the globe, Cipla, the Indian upstart pharmaceutical company, took on the giant drug companies by manufacturing Antiflu, a cheaper generic version of the erstwhile available viral drug Tamiflu. With approval from WHO certifying that its drug Antiflu was as effective as Tamiflu, Cipla entered into a deal to sell its Antiflu at cheaper prices. With Roche, as the only patent holder of the existing swine flu drug Tamiflu, governments in various countries were stockpiling it to prevent fatalities from complications associated with the swine flu. With projections estimating that a large chunk of the world's population would become infected with swine flu, experts were of the opinion that the floodgates could open up for upstart companies like Cipla to offer cheaper generic drugs. It remained to be seen whether with a looming swine flu epidemic threatening to infect the entire planet, Cipla's venture to produce cheaper generic versions of a drug required to combat a global health crisis, would be able to yield the desired outcome.

Settings

Location:
Industry:
Other setting(s):
2009-2010

Related